| Budesonide/formoterol maintenance and reliever therapy | Conventional best practice |
Subjects n | 772 | 766 |
Any adverse events | 474 (61.4) | 491 (64.1) |
Total serious adverse events | 17 (2.2) | 15 (2.0) |
Serious adverse events leading to death | 1 (0.1) | 2 (0.3) |
Serious adverse events not leading to death | 16 (2.1) | 13 (1.7) |
Discontinuations of study treatment | | |
Due to adverse events | 27 (3.5) | 7 (0.9) |
Due to asthma worsening or exacerbation | 9 (1.2) | 3 (0.4) |
Due to a severe asthma exacerbation | 4 (0.5) | 3 (0.4) |
Due to a serious adverse event | 3 (0.4) | 3 (0.4) |